Tuberculosis disease propagation and implications for drug discovery
  • Vincent Delorme Ph.D
  • SLS Colloquia / May 9th 04:00 pm / bldg.110 room N104

Mycobacterium tuberculosis (Mtb) is the major etiologic agent for tuberculosis in human. This terrible disease was responsible for 1.6 million deaths globally in 2017, and 10 million new people were estimated to have been newly infected in the same year. Mtb is an obligate human pathogen, able to efficiently infect the lungs and establish long-term, asymptomatic infections hidden from the immune system, before eventually triggering a burst phase of extensive caseous pneumonia and cavitation for transmission to new hosts. Here, we will review the cascade of events leading to the active disease, based on available histopathological evidence, and explain the concepts and misconceptions about latent tuberculosis infection (LTBI).

These considerations will help us understand why the clinical treatment of tuberculosis is so difficult and lengthy, despite the use of extremely potent antibiotics. We will also highlight the necessity for developing well-understood drug combination regimens, and emphasize how drug-resistant Mtb can be a major threat to the successful control of the global tuberculosis epidemic. Finally, we will summarize some of the work done and on-going at Institut Pasteur Korea to try to tackle the gaps in drug discovery and development.



Keywords: Mycobacterium tuberculosis (Mtb), latent & active tuberculosis, drug-resistance, drug development